Data as of Apr 17
 -0.18 / -6.04%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Oxigene, Inc. engages in the development of therapeutics to treat cancer and eye diseases. It offers anti-vascular drugs referred to as vascular disrupting agents. Its products include Zybrestat (fosbretabulin) and Zybrestat Topical. The company was founded in 1988 and is headquartered in South San Francisco, CA.

Contact Information

Oxigene, Inc.
701 Gateway Boulevard
South San Francisco California 94080
P:(650) 635-7000
Investor Relations:



Other institutional15.72%
Mutual fund holders0.72%
Individual stakeholders0.69%

Top Executives

Peter J. LangeckerPresident, Chief Executive Officer & Director
Barbara RichingChief Financial Officer & Vice President
Jai BalkissoonVice President-Clinical Development
Kathleen M. LeeVice President-Chemistry, Manufacturing & Controls
Ronald W. PeroFounding Member

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.